Alexipharmic Drugs Market Share

Market Share of Alexipharmic Drugs Industry

The alexipharmic drugs market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some prominent players are developing new products with lesser side effects and launching across the world. In October 2018, The National Agency for the Safety of Medicines and Healthcare Products (ANSM) granted marketing authorization to Ethypharm for its drug Baclocur in France for the first time in the world. Baclocur is a range of baclofen tablets in doses of 10, 20 and 40 mg prescribed for alcohol-dependent adult patients with high-risk alcohol consumption. Launch of such medication-assisted treatment (MAT) products will positively impact the market growth over the course of the forecast period. Some of the companies which are currently dominating the market are Bausch Health Companies Inc, Fresenius SE & Co. KGaA (Fresenius Kabi), Ethypharm S. A., Mylan N.V., and Emergent BioSolutions

Alexipharmic Drugs Market Leaders

1. Fresenius SE & Co. KGaA (Fresenius Kabi)

2. Mylan N.V.

3. Ethypharm S.A.

4. Emergent BioSolutions Inc

5. Bausch Health Companies Inc.

*Disclaimer: Major Players sorted in no particular order